CARESIDE INC | TalkMarkets | Page 1
No data available
No data available

People who follow this stock (34)

Latest Posts

About This Stock More About This Stock
Week In Review: LianBio To Close Operations; Will Pay $528 Million To Shareholders
Article By: ChinaBio® Today
Saturday, February 17, 2024 2:20 PM EST
LianBio, a Princeton-Shanghai biotech, has decided to call it quits. LianBio plans to stop all of its operations by the end of 2024, and it will distribute a $4.80 dividend/share ($528 million) to its shareholders.
In this article: AZN, CASI, CHGCY, LIAN
Read
Week In Review: Alphamab Oncology Plans $350 Million Hong Kong IPO
Article By: ChinaBio® Today
Saturday, December 7, 2019 5:15 PM EST
Alphamab Oncology, a company developing eight bispecifics for oncology, plans to stage an IPO before the end of the year on the Hong Kong Exchange that could raise up to $350 million.
In this article: AZN, JNJ, MRK, CASI, ASLN
Read
Week In Review: Chi-Med Plans $500 Million Hong Kong IPO
Article By: ChinaBio® Today
Saturday, April 20, 2019 4:48 PM EST
Hutchison China MediTech filed to IPO on the Hong Kong Exchange, following listings in London and on NASDAQ, where it has a market capitalization of over $4 billion. The IPO is expected to raise between $300 million and $500 million.
In this article: RNN, CASI, HCM
Read
Week In Review: Inventis Closes $70 Million Financing To Develop 30 Novel Therapeutics
Article By: ChinaBio® Today
Saturday, March 16, 2019 4:22 PM EST
InventisBio of Shanghai closed a $70 million Series C financing led by Advantech Capital and CMBI, followed by Pudong Innotek. Founded in 2013, InventisBio focuses on discovering and developing novel therapeutics for cancer and metabolic diseases.
In this article: CASI, NTRA
Read
Week In Review: Grifols Pays $1.9 Billion For 26% Stake In Shanghai RAAS
Article By: ChinaBio® Today
Saturday, March 9, 2019 4:13 PM EST
Grifols, a Barcelona maker of plasma-based medicines, acquired a 26% stake in Chinese blood plasma company Shanghai RAASfor $1.9 billion in a non-cash deal. Grifols will exchange a 45% ownership in Grifols Diagnostic Solutions for the RAAS stake.
In this article: CASI, BGNE, GRFS, NVO
Read

Latest Tweets for $CASI

No tweets yet!

PARTNER HEADLINES